Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 23 Aug 2021
Xeljanz (tofacitinib citrate) receives marketing authorisation in the European Union for the treatment of active polyarticular juvenile idiopathic arthritis and juvenile psoriatic arthritis
20 August 2021 - Pfizer announced today that the European Commission has approved Xeljanz (tofacitinib) for the treatment of active polyarticular ...
Posted by Michael Wonder on 23 Aug 2021
TGA grants provisional determination to Celltrion Healthcare's anti-viral COVID-19 treatment regdanvimab
23 August 2021 - On 20 August 2021 the TGA granted provisional determination to Celltrion Healthcare in relation to regdanvimab. ...
Posted by Michael Wonder on 23 Aug 2021
TGA grants provisional determination to Roche combination COVID-19 treatment casirivimab and imdevimab (Ronapreve)
23 August 2021 - On 20 August 2021 the TGA granted provisional determination to Roche in relation to the combination ...
Posted by Michael Wonder on 23 Aug 2021
ATAGI update following weekly COVID-19 meeting (18 August 2021)
23 August 2021 - ATAGI met on Wednesday 18 August 2021 to review the latest developments relating to COVID-19 and COVID-19 ...
Posted by Michael Wonder on 23 Aug 2021
Dulaglutide receives Medsafe approval
23 August 2021 - Dulaglutide will be funded from 1 September 2021. ...
Posted by Michael Wonder on 22 Aug 2021
White House to House Democrats: drug price plan is a winning issue
22 August 2021 - The Biden administration is touting the popularity of its prescription drug proposal as it works to convince ...
Posted by Michael Wonder on 22 Aug 2021
Accelerated approval - an unexpected pathway to value-based pricing?
18 August 2021 - Accelerated approval is an important regulatory pathway that provides early access to treatments for patients with serious ...
Posted by Michael Wonder on 22 Aug 2021
TGA approves new COVID-19 treatment for use in Australia
20 August 2021 - Australians with COVID-19 who are at risk of hospitalisation will now have access to an additional antibody ...
Posted by Michael Wonder on 21 Aug 2021
Competition, consolidation and evolution in the pharmacy market
12 August 2021 - Implications for efforts to contain drug prices and spending. ...
Posted by Michael Wonder on 21 Aug 2021
Cystic fibrosis patients, advocates urge Ontario government to provide ‘miracle drug’ funding
20 August 2021 - An Ontario teen living with Cystic Fibrosis and her mother are hoping to shine a light ...
Posted by Michael Wonder on 20 Aug 2021
FDA approves nivolumab for adjuvant treatment of urothelial carcinoma
20 August 2021 - On 19 August 2021, the FDA approved nivolumab (Opdivo, Bristol-Myers Squibb) for the adjuvant treatment of ...
Posted by Michael Wonder on 20 Aug 2021
UK authorises Regeneron antibody cocktail to prevent and treat acute COVID-19 infection
20 August 2021 - UK chief medical officers to confirm how antibody cocktail will be rolled-out on the National Health ...
Posted by Michael Wonder on 20 Aug 2021
NICE draft guidance extends recommendation for sapropterin to pregnant women and people aged up to 22 years with rare inherited metabolic condition phenylketonuria
20 August 2021 - NICE has today issued final draft guidance which now recommends sapropterin (Kuvan; BioMarin) as an option for ...
Posted by Michael Wonder on 20 Aug 2021
Bristol Myers Squibb receives European Commission approval for Abecma (idecabtagene vicleucel), the first anti-BCMA CAR T cell therapy for relapsed and refractory multiple myeloma
19 August 2021 - Abecma represents the only cell therapy approved for multiple myeloma. ...
Posted by Michael Wonder on 20 Aug 2021
Acting FDA Chief Janet Woodcock ruled out as Biden nominee
19 August 2021 - Woodcock faced backlash over controversial Alzheimer’s drug. ...